W
hile it is well recognized that some patients with multiple sclerosis (MS) can either present with or develop severe cognitive impairment during the course of their disease, the mechanisms underlying severe cognitive dysfunction in MS are not well understood. 1 Here, we report on a patient with MS who developed severe cognitive impairment associated with intrathecal antibodies to the NR1 subunit of the N-methyl-D-aspartate receptor (NMDAR).
Report of a Case
A 33-year-old woman developed bilateral plantar paresthesia and numbness in her right leg in June 2002. Five years before, an episode of blurred vision in both eyes had resolved spontaneously. Neurological examination revealed a mild spastic paraparesis and hypesthesia of the right leg. Cranial magnetic resonance imaging (MRI) showed disseminated periventricular hyperintense lesions and cerebrospinal fluid (CSF) examination findings revealed a white blood cell count of 9/μL (reference range, <5/μL; to convert to ×10 9 per liter, multiply by 0.001) and CSF-specific oligoclonal bands. She was diagnosed as having relapsing-remitting MS and was prescribed immunomodulatory therapy with glatiramer acetate, 20 mg/d subcutaneous. In an attempt to reverse her cognitive deterioration, immunosuppressive therapy was initiated with high-dose intravenous corticosteroids, followed by oral corticosteroids and azathioprine, which was switched to monthly intravenous cyclophosphamide (700 mg/m 2 body surface) in July 2006. However, formal neuropsychological testing in January 2007 showed no improvement of her cognitive deficits and the patient stopped therapy owing to lack of efficacy in April 2007. Subsequently, her disease exacerbated at the end of 2007, when she developed intercurrent delusions, behavioral abnormalities, and progressive gait ataxia. A cerebral MRI demonstrated at least 5 contrast-enhancing lesions and she eventually started treatment with monthly natalizumab infusions in January 2008. This therapy was associated with improvement of motor functions but no significant effect on cognitive symptoms; therefore, she had to be taken care of in a nursing home starting in 2008. In October 2011, after 33 months of natalizumab therapy, the patient was readmitted to our hospital because of progressive memory deficits and behavioral changes including aggressiveness. On examination, she was disoriented to place and time. She had a severe amnesic syndrome; for instance, she was unable to recall whether she had eaten half an hour after she had lunch. Her Mini-Mental State Examination score was 14 out of 30. No JC virus DNA was detectable in the CSF, arguing against progressive multifocal leukoencephalopathy. Given the unusual clinical picture, CSF and serum samples were tested for antibodies associated with autoimmune encephalitides. While no antibodies to Hu, Ri, Yo, Tr, Ma/Ta, glutamic acid decarbox- . Because of the increased risk for progressive multifocal leukoencephalopathy after more than 2 years of natalizumab treatment and prior immunosuppressive therapy, natalizumab was discontinued. Five months after natalizumab withdrawal, the patient developed a fulminant relapse with somnolence, inability to walk, and urinary retention. Cerebral and spinal MRI both revealed new lesions (Figure 1D-F) . Findings from CSF examination showed an increased anti-NMDAR IgG titer (1:32; eFigure in the Supplement), but serum anti-NMDAR IgG was negative, again demonstrating intrathecal production of anti-NMDAR IgG antibodies. After intravenous corticosteroids and 6 courses of plasma exchange, the patient improved to her prerelapse level of functioning. She was subsequently treated with immunosuppressive therapy with mitoxantrone and tapered oral corticosteroids, which was associated with a certain stabilization and a reduction of anti-NMDAR IgG in CSF (titer, 1:10; October 2013). Still, her general condition deteriorated and she eventually died following urosepsis at the end of 2013. There was no postmortem examination. Figure 2 summarizes her clinical course and anti-NMDAR IgG antibody findings.
Written informed consent for this report was obtained from the patient's family.
Discussion
The initial presentation of the patient described in this report appears typical of MS, and she fulfilled both current clinical and MRI diagnostic criteria for MS. 2 However, her subsequent disease course was characterized by an unusually severe and progressive cognitive decline, with marked impairment of anterograde memory as the most prominent deficit. Detection of intrathecally produced NMDAR IgG, which is highly specific for anti-NMDAR encephalitis, 3, 4 at the time of symptom onset and during a relapse following natalizumab withdrawal suggests that the patient's cognitive impairment and further neuropsychiatric symptoms were related to these antibodies. Indeed, persistent cognitive impairments, mainly affecting memory and executive functions, were observed in 8 of 9 patients who underwent comprehensive neuropsychological assessment at a median of 43 months after acute anti-NMDAR encephalitis. exclude that our patient's entire disease process was related to NMDAR antibodies, we feel that given the characteristic initial course and the MS-typical paraclinical findings, our patient had a true co-incidence of MS and NMDAR encephalitis.
In the only other patient with MS and anti-NMDAR encephalitis described so far, diagnosis was based on the detection of antibodies to the NMDAR NR2B subunit in CSF. 7 Because anti-NMDAR antibodies in patients with anti-NMDAR encephalitis are directed against the NR1 subunit of the NMDAR and only rarely codetect NR2B, 3 to our knowledge, we believe this to be the first report of a patient with MS with the characteristic laboratory finding of anti-NMDAR encephalitis.
A diagnostic reevaluation at the onset of cognitive symptoms also revealed Sjögren syndrome. A thorough rheumatologic diagnostic performed at that time excluded systemic manifestations of Sjögren syndrome. In particular, there was no evidence of cerebral or other organ vasculitis. Altogether, we feel that MS and Sjögren syndrome coexisted in our patient, as previously described in other cases, 8 but consider it very unlikely that her disease was due to neurological manifestations of Sjögren syndrome rather than to MS.
The patient had a fulminant relapse after cessation of natalizumab, reminiscent of previous observations on rebound disease activity following natalizumab withdrawal. 9 This relapse was associated with an increase of the anti-NMDAR IgG titer in CSF. CD138 + plasma cell levels in the CSF of natalizumab-treated patients with MS are significantly lower compared with patients with other neurological diseases and untreated patients with MS but increase after discontinuation of natalizumab. 10 Therefore, it seems plausible that natalizumab withdrawal facilitated entry of NMDAR antibody-producing plasma cells to the central nervous system.
Conclusions
This report opens the possibility that severe cognitive impairment or other neuropsychiatric abnormalities in patients with MS may in some instances be related to superimposed antibody-mediated encephalitides. The diagnosis of those patients will require a high degree of clinical suspicion as cognitive symptoms are rather frequent in MS and may mask or be confounded with features of antibody-mediated encephalitides. Nevertheless, testing for antineuronal antibodies appears warranted in patients with MS with unusual neuropsychiatric symptoms. Although various immunotherapies could not reverse cognitive impairments in our patient, antibodymediated encephalitides can respond to treatment, and immunotherapy should be considered in such cases.
